IO Biotech, Inc. (IOBT)

Market Cap	65.22M
Revenue (ttm)	n/a
Net Income (ttm)	-95.49M
Shares Out	65.88M
EPS (ttm)	-1.45
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	52,285
Open	1.0100
Previous Close	0.9850
Day's Range	0.9500 - 1.0200
52-Week Range	0.6600 - 1.7900
Beta	0.09
Analysts	Strong Buy
Price Target	9.33 (+842.42%)
Earnings Date	May 20, 2025

About IOBT

IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company’s lead therapeutic cancer vaccine candidate includes IO102-IO103, which targets cancer cells and immune-suppressive cells in the tumor microenvironment that express indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, and melanoma cancer. It...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 5, 2021
• Employees: 80
• Stock Exchange: NASDAQ
• Ticker Symbol: IOBT
• Website: https://www.iobiotech.com

Analyst Forecast

According to 3 analysts, the average rating for IOBT stock is "Strong Buy." The 12-month stock price forecast is $9.33, which is an increase of 842.42% from the latest price.

Price Target

$9.33

(842.42% upside)

Analyst Consensus: Strong Buy